v3.25.2
Discontinued Operations - Discontinued Operations (Details) - Discontinued Operations, Disposed of by Sale [Member] - Dermavant [Member]
$ in Thousands
3 Months Ended
Jun. 30, 2024
USD ($)
Discontinued Operations [Abstract]  
Revenue, net $ 47,142
Operating expenses:  
Cost of revenues 3,765
Research and development 12,701
Selling, general and administrative 48,626
Total operating expenses 65,092
Loss from operations (17,950)
Change in fair value of debt (119,352)
Interest expense 13,399 [1]
Other income, net (1,782)
Income from discontinued operations before income taxes 89,785
Income tax expense 692
Income from discontinued operations, net of tax 89,093
Loss from discontinued operations before income taxes attributable to noncontrolling interests (155)
Income from discontinued operations before income taxes attributable to Roivant Sciences Ltd. 89,940
Share-based compensation 2,780
Change in fair value of debt (119,352)
Depreciation and amortization 2,834
Product Revenue, Net [Member]  
Discontinued Operations [Abstract]  
Revenue, net 18,367
License, Milestone and Other Revenue [Member]  
Discontinued Operations [Abstract]  
Revenue, net $ 28,775
[1] Interest expense consists of interest payments related to outstanding debt held by Dermavant as well as the associated non-cash amortization of debt discounts and issuance costs.